AI assistant
BioXcel Therapeutics, Inc. — Director's Dealing 2019
Aug 23, 2019
34564_dirs_2019-08-23_ad92b0bf-432d-41f6-be71-2ccf39b46c08.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BioXcel Therapeutics, Inc. (BTAI)
CIK: 0001720893
Period of Report: 2019-08-21
Reporting Person: MUELLER PETER (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-08-21 | Common Stock | P | 1800 | $8.42 | Acquired | 160120 | Direct |
| 2019-08-22 | Common Stock | P | 6646 | $8.83 | Acquired | 166766 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. The shares were acquired in multiple transactions at prices ranging from $8.29 to $8.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. The shares were acquired in multiple transactions at prices ranging from $8.43 to $9.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the SEC, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote.